Hua Lan's research while affiliated with The Third Xiangya Hospital of the Central South University and other places

... SPs are a new type of simulated patient characterized by their ability to mimic the progression and reactions of real patients, thus integrating academic knowledge with clinical practice [16,17]. They have been widely used in clinical internships and have achieved good teaching results [18,19]. The combined application of SPs with other teaching methods, such as PBL, CBL, and mind mapping, has also further improved teaching effectiveness [20,21]. ...

... The results, as shown in Figure 2B, showed that there was a significant difference in the expression of SKA1 between cancerous and paracancerous tissues (P=0.015). Many previous studies have demonstrated the important role of SKA1 in the malignant transformation and progression of multiple cancer types, because this gene can regulate various signaling pathways to affect tumor cell growth and metastasis [6]. Increasing clinical evidence has indicated that poor clinical prognosis, tumor invasion, and metastasis are all connected to increased SKA1 expression in a wide variety of cancers, including non-small cell lung cancer, bladder cancer, and hepatocellular carcinoma [7][8][9]. ...

... In thyroid cancer, KCNK1 can promote tumour malignancy through cell cycle, PI3K and MAPK signalling pathways [16]. Promoter hypermethylation causes aberrant expression of KCNK1 and promotes BRCA cell proliferation and migration [20]. Nevertheless, studies on the differential expression of KCNK1 in BC are still lacking, and the molecular mechanisms and biological functions of KCNK1 in BC are unclear. ...

... Minichromosome maintenance complex (MCM) genes play important roles in the process of DNA replication and cell cycle. MCM2 belongs to MCM family and participate in the regulation of cell proliferation and the development of cancers [45]. Elevated MCM2 has been found in pan-cancer and is associated with TMB, stage, immunotherapy response and dismal prognosis, indicating that MCM2 acts as a potential target for cancer immunotherapy [45]. ...

... Recently, T Cell Differentiation Protein 2 (MAL2) emerged as a potential driver of cancer immune escape and novel therapeutic target [7]. MAL2 was overexpressed in tumors and was associated with poor prognosis, and MAL2 knockdown improved major histocompatibility complex type 1 (MHC-1) recognition on tumor surfaces by CD8 + T cells, highlighting the role of MAL2 in immune regulation [8][9][10][11]. While the exact mechanism remains unknown, reducing MAL2 expression may be a novel therapeutic approach. More research is needed to fully understand the protein potential. ...

... Upregulation of NCAPH expression was significantly associated with hypomethylation [54]. Hua and colleagues used a variety of databases to describe a series of changes in MCM in EC, and they concluded that the mRNA and protein levels of MCMs were greatly increased in individuals with EC, while the average methylation level in the promoter region of MCM was dramatically reduced [55]. ...

... Although this approach can achieve complete remission in most patients, unfortunately, due to inherent/acquired drug resistance and severe adverse side effects, most patients are intolerant or refractory to platinum-based chemotherapy, resulting in low overall survival (6). Tumor cell spread and drug resistance lead to tumor relapse, thereby causing psychological and physical harm (7). Natural products from plants or their derivatives are critical sources of anti-tumor drugs, such as vincristine, vincaleukoblastinum, irinotecan, and topotecan, etc., which are provided with unique advantages owing to their multi-target function, extensive availability and long application history (8,9). ...

... In recent years, several studies have used methods such as WGCNA, RF, and LASSO to reveal the related risk factors and potential mechanisms of immune escape in different tumors [33,34]. For example, Zhong et al. [33] mainly used WGCNA to reveal that syndecan-1 may be related to immune infiltration and regulate AP. ...

... *p-value < 0.05; **p-value < 0.01; ***p-value < 0.001; ****p-value < 0.0001 and OV prognosis, none of the previous autophagyrelated signatures have been applied to clinical practice yet, partly due to limitations in sensitivity and specificity. Chen and colleagues constructed and validated an autophagy-related 7-gene signature for OV prognosis [32]. However, only 4 out of the 7 ATGs played significant prognostic roles in OV, including ATG12, GABARAPL1, ULK2, and IFNG, while ATG4A, ATG4C, and ATG5 were not statistically significant (p-value ≥ 0.05). ...

... stands for tumor immune dysfunction and rejection. It is a computational framework for assessing the likelihood of tumor immune escape in the gene expression profile of tumor samples [30]. In our study, the TIDE values of samples in the high-risk group were significantly higher than those in the low-risk group (p < 0.0001), indicating a higher likelihood of immune escape in the tumor cells of the high-risk group. ...